ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ENSC • US2936025046

0.41 USD
-0.03 (-7.01%)
At close: Feb 11, 2026
0.41 USD
0 (0%)
After Hours: 2/11/2026, 4:03:21 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall ENSC gets a fundamental rating of 3 out of 10. We evaluated ENSC against 523 industry peers in the Biotechnology industry. The financial health of ENSC is average, but there are quite some concerns on its profitability. ENSC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ENSC has reported negative net income.
  • ENSC had a negative operating cash flow in the past year.
  • ENSC had negative earnings in 4 of the past 5 years.
  • In the past 5 years ENSC always reported negative operating cash flow.
ENSC Yearly Net Income VS EBIT VS OCF VS FCFENSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

  • ENSC has a worse Return On Assets (-345.10%) than 92.16% of its industry peers.
  • The Return On Equity of ENSC (-911.79%) is worse than 78.78% of its industry peers.
Industry RankSector Rank
ROA -345.1%
ROE -911.79%
ROIC N/A
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENSC Yearly ROA, ROE, ROICENSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

  • ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENSC Yearly Profit, Operating, Gross MarginsENSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ENSC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ENSC has been reduced compared to 5 years ago.
  • ENSC has a better debt/assets ratio than last year.
ENSC Yearly Shares OutstandingENSC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENSC Yearly Total Debt VS Total AssetsENSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ENSC has an Altman-Z score of -69.64. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
  • ENSC's Altman-Z score of -69.64 is on the low side compared to the rest of the industry. ENSC is outperformed by 92.73% of its industry peers.
  • There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -69.64
ROIC/WACCN/A
WACCN/A
ENSC Yearly LT Debt VS Equity VS FCFENSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that ENSC should not have too much problems paying its short term obligations.
  • ENSC's Current ratio of 1.27 is on the low side compared to the rest of the industry. ENSC is outperformed by 82.79% of its industry peers.
  • A Quick Ratio of 1.27 indicates that ENSC should not have too much problems paying its short term obligations.
  • The Quick ratio of ENSC (1.27) is worse than 82.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
ENSC Yearly Current Assets VS Current LiabilitesENSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.48% over the past year.
  • ENSC shows a small growth in Revenue. In the last year, the Revenue has grown by 1.51%.
  • The Revenue has been growing by 13.86% on average over the past years. This is quite good.
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-222.86%
Revenue 1Y (TTM)1.51%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%-85.58%

3.2 Future

  • ENSC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.64% yearly.
  • ENSC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 176.07% yearly.
EPS Next Y64%
EPS Next 2Y40.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-10.84%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENSC Yearly Revenue VS EstimatesENSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2027 20M 40M 60M 80M
ENSC Yearly EPS VS EstimatesENSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1K -2K -3K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENSC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENSC Price Earnings VS Forward Price EarningsENSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENSC Per share dataENSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • ENSC's earnings are expected to grow with 40.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.64%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ENSC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (2/11/2026, 4:03:21 PM)

After market: 0.41 0 (0%)

0.41

-0.03 (-7.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-09
Inst Owners7.48%
Inst Owner Change11.7%
Ins Owners0.29%
Ins Owner Change0%
Market Cap1.45M
Revenue(TTM)4.49M
Net Income(TTM)-10.97M
Analysts82.86
Price Target25.73 (6175.61%)
Short Float %5.96%
Short Ratio0.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.92%
Min EPS beat(2)-46.21%
Max EPS beat(2)34.36%
EPS beat(4)2
Avg EPS beat(4)9.75%
Min EPS beat(4)-46.21%
Max EPS beat(4)54.8%
EPS beat(8)5
Avg EPS beat(8)24.08%
EPS beat(12)9
Avg EPS beat(12)31.22%
EPS beat(16)11
Avg EPS beat(16)-101.82%
Revenue beat(2)1
Avg Revenue beat(2)37.92%
Min Revenue beat(2)-30.95%
Max Revenue beat(2)106.79%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-86.67%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-12.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.57%
Revenue NY rev (1m)100%
Revenue NY rev (3m)34.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-6.37
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS1.27
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -345.1%
ROE -911.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z -69.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-222.86%
EPS Next Y64%
EPS Next 2Y40.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.51%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%-85.58%
Revenue Next Year-10.84%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y-74.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y41.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.63%
OCF growth 3YN/A
OCF growth 5YN/A

ENSYSCE BIOSCIENCES INC / ENSC FAQ

Can you provide the ChartMill fundamental rating for ENSYSCE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to ENSC.


What is the valuation status for ENSC stock?

ChartMill assigns a valuation rating of 1 / 10 to ENSYSCE BIOSCIENCES INC (ENSC). This can be considered as Overvalued.


Can you provide the profitability details for ENSYSCE BIOSCIENCES INC?

ENSYSCE BIOSCIENCES INC (ENSC) has a profitability rating of 0 / 10.


How financially healthy is ENSYSCE BIOSCIENCES INC?

The financial health rating of ENSYSCE BIOSCIENCES INC (ENSC) is 5 / 10.